Ramos-Casals Manuel, la Civita Luca, de Vita Salvatore, Solans Roser, Luppi Mario, Medina Francisco, Caramaschi Paola, Fadda Patrizia, de Marchi Ginevra, Lopez-Guillermo Armando, Font Josep
Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, School of Medicine, University of Barcelona, Barcelona, Spain.
Arthritis Rheum. 2007 Feb 15;57(1):161-70. doi: 10.1002/art.22476.
To characterize the clinical and immunologic patterns of expression, response to therapy, and outcome of patients with Sjögren's syndrome (SS) and associated hepatitis C virus (HCV) infection who developed B cell lymphoma.
Various international reference centers constituted a multicenter study group with the purpose of creating a registry of patients with SS-HCV who developed B cell lymphoma. A protocol form was used to record the main characteristics of SS, chronic HCV infection, and B cell lymphoma.
Twenty-five patients with SS-HCV with B cell lymphoma were included in the registry. There were 22 (88%) women and 3 (12%) men (mean age 55, 58, and 61 years at SS, HCV infection, and lymphoma diagnosis, respectively). The main extraglandular SS manifestations were cutaneous vasculitis in 15 (60%) patients and peripheral neuropathy in 12 (48%); the main immunologic features were positive rheumatoid factor (RF) in 24 (96%) and type II cryoglobulins in 20 (80%). The main histologic subtypes were mucosa-associated lymphoid tissue (MALT) lymphoma in 11 (44%) patients, diffuse large B cell lymphoma in 6 (24%), and follicular center cell lymphoma in 6 (24%). Fifteen (60%) patients had an extranodal primary location, most frequently in the parotid gland (5 patients), liver (4 patients), and stomach (4 patients). Twelve (52%) of 23 patients died after a median followup from the time of lymphoma diagnosis of 4 years, with lymphoma progression being the most frequent cause of death. Survival differed significantly between the main types of B cell lymphoma.
Patients with SS-HCV and B cell lymphoma are clinically characterized by a high frequency of parotid enlargement and vasculitis, an immunologic pattern overwhelmingly dominated by the presence of RF and mixed type II cryoglobulins, a predominance of MALT lymphomas, and an elevated frequency of primary extranodal involvement in organs in which HCV replicates (exocrine glands, liver, and stomach).
描述干燥综合征(SS)合并丙型肝炎病毒(HCV)感染且发生B细胞淋巴瘤患者的临床和免疫表达模式、对治疗的反应及预后。
多个国际参考中心组成了一个多中心研究小组,旨在建立一个SS-HCV且发生B细胞淋巴瘤患者的登记册。使用一份协议表格记录SS、慢性HCV感染和B细胞淋巴瘤的主要特征。
登记册纳入了25例SS-HCV合并B细胞淋巴瘤患者。其中女性22例(88%),男性3例(12%)(SS、HCV感染和淋巴瘤诊断时的平均年龄分别为55岁、58岁和61岁)。主要的腺外SS表现为15例(60%)患者出现皮肤血管炎,12例(48%)患者出现周围神经病变;主要的免疫特征为24例(96%)患者类风湿因子(RF)阳性,20例(80%)患者出现II型冷球蛋白。主要组织学亚型为11例(44%)患者为黏膜相关淋巴组织(MALT)淋巴瘤,6例(24%)为弥漫性大B细胞淋巴瘤,6例(24%)为滤泡中心细胞淋巴瘤。15例(60%)患者有结外原发部位,最常见于腮腺(5例)、肝脏(4例)和胃(4例)。23例患者中有12例(52%)在淋巴瘤诊断后中位随访4年时死亡,淋巴瘤进展是最常见的死亡原因。B细胞淋巴瘤的主要类型之间生存率差异显著。
SS-HCV合并B细胞淋巴瘤患者的临床特征为腮腺肿大和血管炎发生率高、免疫模式以RF和混合型II型冷球蛋白的存在为主导、MALT淋巴瘤占优势以及HCV复制器官(外分泌腺、肝脏和胃)结外原发受累频率升高。